Wuxi Vision Pro Completes B Round Financing of $12.6 Million


SHANGHAI—Wuxi Vision Pro Ltd., a manufacturer of intraocular lenses based in China, announced that it has completed B round financing of $12.6 million. The investors are Qiming Venture Partners and Ruijian Capital. “With modern science and technology drastically changing human behaviors, excessive use of the human eyes has accelerated the aging of eyes and developing other eye disease among young people,” said Dr. Liao Xiugao, founder of Wuxi Vision Pro. “These factors promote the need of rapid development of ophthalmic medical products. My company commits to researching and developing high-quality ophthalmic products and create a leading brand to meet the growing demand.”

The number of potential cataract patients over 60 years old in China is estimated at 130 million, according to Wuxi Vision Pro. Cataract surgery today in China has a 20 percent growth rate per year, and the cataract surgery rate (CSR) per million will reach more than 3,500 in 2020, the company said.

Wuxi Vision Pro has its own lens materials development and manufacturing facility in Irvine, Calif. Its products have been used by many manufacturers worldwide. The company’s Leiming brand aspheric intraocular lenses has obtained CFDA approval and CE certificate.